BCRX Q2 2020 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+98.3% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$39M-1341.3% margin

Net Income

-$39M-1344.7% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-40.5%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$215M

Total Liabilities

$138M

Stockholders' Equity

$77M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+98.3%
Gross Profit	$3M	$1M	+101.9%
Operating Income	-$39M	-$35M	-10.3%
Net Income	-$39M	-$38M	-2.6%

Revenue Segments

Collaborative and Other Research and Development

$3M98%

Royalty

$44,0002%